Format

Send to

Choose Destination
Pediatr Neurol. 2009 Apr;40(4):289-94. doi: 10.1016/j.pediatrneurol.2008.11.004.

Urolithiasis with topiramate in nonambulatory children and young adults.

Author information

1
Pediatric Neurology Department, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA. Monisha.Goyal@uhhospitals.org

Abstract

Urolithiasis occurs infrequently in the pediatric population, where metabolic factors play a primary role in the pathogenesis of stone formation. Topiramate, an antiepileptic drug, is associated with a kidney stone in 1.5% of patients in published clinical trials. However, this risk may be much higher in certain populations with multiple preexisting risk factors. We performed a retrospective review of all nonambulatory and neurologically impaired individuals in a long-term care facility. Three groups were involved: those with no exposure to antiepileptic drugs, those on antiepileptic drugs other than topiramate, and those who had been treated with topiramate. Thirteen of 24 (54%) individuals on topiramate monotherapy or polytherapy developed clinical evidence of urolithiasis after a mean duration of 36.4 months. Our results suggest that nonambulatory and neurologically impaired individuals in a long-term care facility appear to be at higher risk of developing kidney stones with topiramate than previously reported.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center